Marked Increase of Activated Factor VII in Uremic Patients

Summary

We investigated plasma activated factor VII (FVIIa) levels in uremic patients (nondialysis group: n = 38; dialysis group: n = 36) and healthy controls (n = 32). We also measured the plasma levels of thrombomodulin (an indicator of endothelial cell injury) and tissue factor. Plasma FVIIa showed a marked increase in the nondialysis group (mean [95% confidence interval]: 4.6 [4.1-5.1] ng/ml, p <0.0001) with the progressive impairment of renal function, as indicated by the serum creatinine level, when compared with the 32 controls (2.8 [2.5-3.1] ng/ml), and was further increased in the dialysis group (6.1 [5.5-6.8] ng/ml, p <0.001 vs. nondialysis group). Plasma levels of thrombomodulin and tissue factor were also higher in the nondialysis group than the control group, and were further increased in the dialysis group. Plasma tissue factor levels did not show any correlation with FVIIa or thrombomodulin in both the nondialysis and dialysis groups. Thus, circulating tissue factor appears to be released by a different mechanism from thrombomodulin and may not contribute to the direct activation of factor VII in uremic patients. On the other hand, the plasma level of thrombomodulin was positively correlated with that of FVIIa in the nondialysis group, and this correlation was independent of renal function. Thus, enhanced conversion of factor VII zymogen to FVIIa, probably related to endothelial cell injury, may be a risk factor for cardiovascular events in uremic patients.

• References

• 1 Meade TW. The epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. eds Churchill Livingstone Inc; London: 1994. pp 1199-1227
• 2 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR S, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 3 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
• 4 Kario K, Matsuo T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992; 67: 105-113
• 5 Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated factor VII: Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb 1994; 14: 265-274
• 6 Kario K, Sakata T, Matsuo T, Miyata T. Factor VII in non-insulin-dependent diabetic patients with microalbuminuria. Lancet 1993; 342: 1552
• 7 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744
• 8 Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE. Iwanaga S: Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa. J Biol Chem 1992; 267: 21329-21337
• 9 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII: activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253-259
• 10 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and disease. Blood 1990; 76: 2024-2029
• 11 Nakamura S, Kamikubo Y, Okajima K, Asakura H, Nakamura K. Plasma tissue factor, its sensitive assay and characterization. Thromb Haemost 1993; 69: 744 (abstract)
• 12 Eberst ME, Berkowitz LR. Hemostasis in renal disease: pathophysiology and management. Am J Med 1994; 96: 168-179
• 13 Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991; 58: 201-204
• 14 Sorensen PJ, Knudsen F, Nielsen AH, Dyerberg J. Protein C assays in uremia. Thromb Res 1989; 54: 301-310
• 15 Faioni EM, Franchi F, Krachmalnicoff A, Valsecchi C, Vigano GL, Remuzzi G, Mannucci PM. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. Thromb Haemost 1991; 66: 420-425
• 16 Toulon P, Jacquot C, Capron L, Frydman M-O, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemost 1987; 57: 263-268
• 17 Turney JH, Woods HF, Fewell MR, Weston MJ. Factor VIII complex in uraemia and effects of haemodialysis. BMJ 1981; 282: 1653-1656
• 18 Yamazaki M, Asakura H, Sato T, Tsugawa Y, Matsumura M, Kawamura Y, Ohka T, Matsuda T. Changes in plasma levels of thrombomodulin during haemodialysis. Blood Coagul Fibrinolysis 1992; 3: 113-117
• 19 Attman P-O, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int (Suppl.) 1991; 39: S-16-S-23
• 20 Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994; 71: 275-279
• 21 Boze Jr GJ. The tissue factor pathway of coagulation: factor VII, tissue factor, and tissue factor pathway inhibitor. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. eds Churchill Livingstone Inc; London: 1994. pp 349-377
• 22 Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439-449
• 23 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
• 24 Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75: 329-336
• 25 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623
• 26 Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost 1990; 63: 157-162
• 27 Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Katsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 84: 343-347